Providers at Nemours Children’s Hospital in Orlando treated a DMD patient with Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl), which the FDA approved June 22 for 4- and 5-year-olds with a DMD gene mutation. The treatment costs $3.2 million.
Elevidys is the first and only approved gene therapy for the rare genetic condition that weakens the body’s muscles. DMD mostly affects males, and between 9,000 and 12,000 people in the U.S. are diagnosed with it, according to Nemours Children’s Hospital.
“Until now, patients have only had treatments to manage their symptoms,” the hospital said in a Sept. 26 news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
